Market Overview

Rodman & Renshaw Sees 243% Upside In OncoSec Medical Shares

Share:
Rodman & Renshaw Sees 243% Upside In OncoSec Medical Shares
Related
OncoSec Reports Positive Results from Phase II Trial of ImmunoPulse IL-12 in MCC
OncoSec Announces First Patient Enrolled in Phase II Clinical Trial Evaluating Combination of ImmunoPulse™ IL-12 and Anti-PD-1 Treatment

Rodman & Renshaw initiated coverage on OncoSec Medical Inc (NASDAQ: ONCS) with a Buy rating and $6.00 price target, describing the company as representing a unique opportunity in the oncology sector, positioned in the highly visible and widely-followed immunotherapy domain.

Related Link: Galencia's Bid For Relypsa Is "Reasonable," Another Bidder "Unlikely"

According to the analysts, several near-term value drivers could constitute meaningful upside to their estimates. "We currently only model sales of ImmunoPulse™ IL-12 in melanoma, without factoring in contributions from other potential therapeutic candidates generated by OncoSec's proprietary technology platform or possible applications in other indications, such as triple-negative breast cancer (TNBC)," the analysts wrote.

They also mentioned three major risks to their valuation, including (1) negative trial data, (2) failure to show synergy with approved immunotherapy drugs, (3) regulatory delays or rejections.

Full ratings data available on Benzinga Pro.

Did you like this article? Could it have been improved? Please email feedback@benzinga.com with the story link to let us know!

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Initiation Analyst Ratings Trading Ideas Best of Benzinga

 

Related Articles (ONCS)

View Comments and Join the Discussion!

Partner Center